Associations between thiazide diuretic use and calciuria in patients with hypoparathyroidism: an observational cohort study
PURPOSE: The standard medical management of chronic hypoparathyroidism includes supplementation with calcium, vitamin D3 (cholecalciferol) and active 1,25-dihydroxyvitamin D (calcitriol), however in severe cases this treatment can be limited by hypercalciuria. In daily clinical practice, thiazide diuretics may be administered to reduce calciuria, but only few data are available on the effects of thiazide use in hypoparathyroidism. The objective of this study was to investigate biochemical and clinical changes in patients receiving thiazide diuretics for the treatment of hypoparathyroidism. METHODS: In this retrospective observational study, we investigated patients receiving thiazide diuretics for the treatment of hypoparathyroidism at our endocrine outpatient clinic. Clinical and biochemical parameters were collected at the time of first presentation, before the initiation of thiazide treatment, and at the time of last check-up. RESULTS: Out cohort includes 145 patients with hypoparathyroidism. 34 patients (23.4%) received thiazides due to higher urinary calcium excretion (UCaE). The subcohort treated with thiazides was monitored for 4.6 years. Under a median dose of 12.5 mg hydrochlorothiazide, UCaE significantly decreased from 9.9 mmol/24 h before hydrochlorothiazide to 6.0 mmol/24 h (p < 0.001) at the last observational visit, corresponding to a mean UCaE reduction by 32.4% (95% CI 19.3-45.5). Serum calcium, magnesium, kidney function and blood pressure remained stable. Thiazide treatment was discontinued in 12 patients (26%), with electrolyte disturbances and vertigo as the most common causes. CONCLUSION: These data indicate that the add-on of hydrochlorothiazide to conventional therapy in patients with hypoparathyroidism significantly lowers calciuria, but does not impact serum calcium, magnesium or kidney function.
Authors
- Gabriele Grimm (ORCID: https://orcid.org/0000-0002-7009-567X)
- Greisa Vila (ORCID: https://orcid.org/0000-0003-1918-1959)
- Christian Scheuba (ORCID: https://orcid.org/0000-0001-7632-2506)
- Alexandra Kautzky‐Willer (ORCID: https://orcid.org/0000-0002-3520-4105)
- Marie Helene Schernthaner-Reiter (ORCID: https://orcid.org/0000-0002-7972-7610)
- Christine Wagenlechner
- A Luger (ORCID: https://orcid.org/0000-0001-5629-6873)
- C Looser
- Philipp Riss
- Anna Elisabeth Nagel
Institutions
- Medical University of Vienna (AT)
Publication Details
- Journal
- Endocrine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1007/s12020-026-04842-x
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medizinische Universität Wien